This year’s predictions on the biopharma financing and funding environment are more optimistic than they were last year, with the persistent caveat of macroeconomic uncertainty, plus unresolved litigation on policy issues such as the Inflation Reduction Act. With deal activity increasing and the promise of novel product approvals in key therapeutic areas next year, however, small biotechs and (some) Big Pharmas appear poised to steer the industry into calmer waters. Business model creativity will become increasingly mandatory for companies marketing expensive products for small patient populations and larger population drugs in categories like obesity and CNS disorders.
